Scandion Oncology announces that its President & CEO has bought 10,800 shares in Scandion OncologyScandion Oncology A/S ("Scandion Oncology") announces that its President &...
Invitation to Scandion Oncology A/S audiocast on May 20, 2021We will publish our Interim Report for Q1 2021 on Thursday, May 20 and will b...
Scandion Oncology welcomes Mads Aaboe Jensen as VP for Business Development and InnovationScandion Oncology announces the appointment of Mads Aaboe Jensen, PhD as VP f...
2021 – a transformative year for Scandion OncologyThe newly released 2020 annual report for Scandion Oncology summarises what w...
Interview with COO and Head of R&D Operations Maj Hedtjärn in BioStockRead the interview with COO and Head of R&D Operations Maj Hedtjärn featu...
Invest TalksRead the interview (in Swedish) with CEO Bo Rode Hansen featured in today’s “...
Great interest at our Year-end 2020 webcastThank you to all attendees who joined our live Year-end 2020 webcast & Q&...
Invitation to Scandion Oncology A/S live webcast on February 19, 2021Invitation to Scandion Oncology A/S live webcast on February 19, 2021 We h...
A great milestoneA great milestone: On Feb. 3rd, 2021, Scandion Oncology was listed as company...
Scandion Oncology tackles antioestrogen resistanceScandion Oncology is currently evaluating its lead candidate SCO-101 ...
